SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Recruiting now · Phase 1
Conditions studied: Human Papillomavirus Associated Carcinomas, Cervical Cancer, Head and Neck Cancers, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, HPV-Related Malignancy
In brief
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Key facts
- Study ID
- NCT06544720
- Run by
- The Affiliated Hospital of Qingdao University
- People needed
- 18
- Starts
- 2023-08-02
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2024-08-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The affiliated hosptial of qingdao university — Qingdao, Shandong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.